Balugrastim biosimilar - Jiangsu T-mab BioPharma

Drug Profile

Balugrastim biosimilar - Jiangsu T-mab BioPharma

Alternative Names: GW-003

Latest Information Update: 04 Apr 2016

Price : $50

At a glance

  • Originator Jiangsu T-mab BioPharma
  • Class Chemoprotectants; Granulocyte colony-stimulating factors
  • Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Neutropenia

Most Recent Events

  • 01 Mar 2016 Jiangsu T-Mab Biopharma initiates enrolment in a phase I trial in Neutropenia (Chemotherapy-induced) in China (SC) (NCT02725606)
  • 01 Dec 2015 Jiangsu T-Mab Biopharma completes a phase I trial in Neutropenia (Chemotherapy-induced) in China (SC) (NCT02156388)
  • 01 Sep 2015 Phase-I clinical trials in Neutropenia (In volunteers, Chemotherapy-induced) in China (SC) (NCT02643901)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top